Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | PPM1B | O75688 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2533909 | 1.00 | CYP1A2 (0.60) | CYP1A2CYP2C9TSHRCYP2C19ALDH1A1 | |
| SCHEMBL2534532 | 1.00 | CYP1A2 (0.60) | CYP1A2CYP2C9TSHRCYP2C19ALDH1A1 | |
| SCHEMBL7227981 | 1.00 | CYP1A2 (0.60) | CYP1A2CYP2C9TSHRCYP2C19ALDH1A1 | |
| SCHEMBL7220705 | 1.00 | CYP1A2 (0.60) | CYP1A2CYP2C9TSHRCYP2C19ALDH1A1 | |
| SCHEMBL2535775 | 0.88 | CYP1A2 (0.50) | CYP1A2CYP2C9TSHRCYP2C19ALDH1A1 | |
| SCHEMBL2534983 | 0.88 | CYP1A2 (0.50) | CYP1A2CYP2C9TSHRCYP2C19ALDH1A1 | |
| SCHEMBL2534980 | 0.88 | CYP1A2 (0.50) | CYP1A2CYP2C9TSHRCYP2C19ALDH1A1 | |
| SCHEMBL1335665 | 0.85 | ALDH1A1 (0.54) | CYP1A2CYP2C9TSHRCYP2C19ALDH1A1 | |
| SCHEMBL16386442 | 0.85 | CYP1A2 (0.56) | CYP1A2CYP2C9TSHRCYP2C19ALDH1A1 | |
| SCHEMBL12699010 | 0.85 | CYP1A2 (0.56) | CYP1A2CYP2C9TSHRCYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3930724-B1 | METHOD AND COMPOSITION FOR INHIBITING VIRUS INFECTION | ARJIL BIOTECH HOLDING COMPANY LTD (TW) | 2024-07-03 | — | — | EP | disclosed |
| US-20240148753-A1 | METHOD AND COMPOSITION FOR REVERSING AND/OR INHIBITING ATHEROSCLEROSIS | Arjil Biotech Holding Company Limited (TW) | 2024-05-09 | — | — | US | disclosed |
| CN-113795258-B | Methods and compositions for inhibiting viral infection | 吉亚生技控股股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| EP-3955947-A1 | METHOD AND COMPOSITION FOR REVERSING AND/OR INHIBITING ATHEROSCLEROSIS | Arjil Biotech Holding Company Limited (TW) | 2022-02-23 | — | — | EP | disclosed |
| US-11253527-B2 | Method and composition for inhibiting virus infection | Arjil Biotech Holding Company Limited (TW) | 2022-02-22 | — | — | US | disclosed |
| EP-3930724-A1 | METHOD AND COMPOSITION FOR INHIBITING VIRUS INFECTION | Arjil Biotech Holding Company Limited (TW) | 2022-01-05 | — | — | EP | disclosed |
| WO-2020214919-A1 | METHOD AND COMPOSITION FOR REVERSING AND/OR INHIBITING ATHEROSCLEROSIS | Arjil Biotech Holding Company Limited (TW) | 2020-10-22 | — | — | WO | disclosed |
| US-20200330485-A1 | METHOD AND COMPOSITION FOR REVERSING AND/OR INHIBITING ATHEROSCLEROSIS | Arjil Biotech Holding Company Limited (TW) | 2020-10-22 | — | — | US | disclosed |
| US-20200268771-A1 | METHOD AND COMPOSITION FOR INHIBITING VIRUS INFECTION | Arjil Biotech Holding Company Limited (TW) | 2020-08-27 | — | — | US | disclosed |
| EP-3415145-A2 | METHOD FOR TREATING STROKE OR REDUCING NERVE INJURY | Arjil Biotech Holding Company Limited (TW) | 2018-12-19 | — | — | EP | disclosed |
| US-20110257164-A1 | DIPEPTIDYL PEPTIDASE IV INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2011-10-20 | — | — | US | disclosed |
| EP-2344463-A2 | 1,2 -THIAZOL YL DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20110082116-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2011-04-07 | — | — | US | disclosed |
| US-7872033-B2 | N-[(5Z)-4-butyl-2-tert-butylisothiazol-5(2H)-ylidene]-5-chloro-2-methoxybenzamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | disclosed |
| US-20100234345-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-09-16 | — | — | US | disclosed |
| WO-2010079413-A2 | DIPEPTIDYL PEPTIDASE IV INHIBITORS | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010054024-A2 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-05-14 | — | — | WO | disclosed |
| EP-2146973-A2 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2010-01-27 | — | — | EP | disclosed |
| US-20090023789-A1 | N-[(5Z)-4-butyl-2-tert-butylisothiazol-5(2H)-ylidene]-5-chloro-2-methoxybenzamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | US | disclosed |
| WO-2008130953-A2 | 2-IMIN0IS0THIAZ0LE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200268771-A1 | METHOD AND COMPOSITION FOR INHIBITING VIRUS INFECTION | HAVCR2, HDGF, ZC3HAV1 | CYP1A2 2185/4885CYP2C9 3048/4885TSHR 4854/4885 |
| US-20090023789-A1 | N-[(5Z)-4-butyl-2-tert-butylisothiazol-5(2H)-ylidene]-5-chloro-2-methoxybenzamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | CNR2, CNR1, TBXA2R | CYP1A2 1304/4885CYP2C9 1950/4885TSHR 192/4885 |
| US-11253527-B2 | Method and composition for inhibiting virus infection | HAVCR2, HDGF, ZC3HAV1 | CYP1A2 2185/4885CYP2C9 3048/4885TSHR 4854/4885 |
| US-20200330485-A1 | METHOD AND COMPOSITION FOR REVERSING AND/OR INHIBITING ATHEROSCLEROSIS | HMGCR, CYP46A1, PCSK9 | CYP1A2 1864/4885CYP2C9 2545/4885TSHR 4402/4885 |
| US-20110082116-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | CYP1A2 1251/4885CYP2C9 1580/4885TSHR 292/4885 |
| US-20110257164-A1 | DIPEPTIDYL PEPTIDASE IV INHIBITORS | DPP4, DPP7, DPP3 | CYP1A2 429/4885CYP2C9 186/4885TSHR 1137/4885 |
| US-20100234345-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | CYP1A2 1266/4885CYP2C9 1462/4885TSHR 285/4885 |
| US-20240148753-A1 | METHOD AND COMPOSITION FOR REVERSING AND/OR INHIBITING ATHEROSCLEROSIS | PCSK9, APOB, PCSK7 | CYP1A2 2468/4885CYP2C9 2727/4885TSHR 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.